Discover why impurity profiling in APIs and excipients is critical for regulatory compliance, patient safety, and resilient pharma supply chains.
The Evolution of Pharmaceutical APIs & Excipients
As the pharmaceutical industry evolves, quality and safety expectations are increasingly shaping supply chain resilience. Strengthening pharmaceutical supply chains now depends on early risk identification, accurate data, material transparency, and independent verification across every stage of API (Active Pharmaceutical Ingredient) and excipient (inactive ingredients) production.
Impurity profiling enables manufacturers to identify, quantify, and control unwanted substances that may affect drug safety, efficacy, and regulatory compliance. More importantly, it provides the data and transparency needed to build resilient, trusted, and compliant pharmaceutical supply networks.
Modern Drug Developments
Modern drug development relies on increasingly sophisticated APIs, novel excipients, complex synthesis routes, and global sourcing strategies. While these advances improve therapeutic performance and manufacturing efficiency, they also introduce new impurity risks, from process related by‑products, and degradation of products, to residual solvents and elemental impurities.
Across the pharmaceutical industry, regulators, manufacturers, and patients are placing greater scrutiny on how APIs and excipients behave throughout their lifecycle. Quality is no longer assessed only in the finished dosage form, but across the entire supply chain, from raw material sourcing and synthesis to formulation, storage, and distribution.
Cotecna supports pharmaceutical manufacturers navigating this shift by providing independent testing, inspection, and certification services that help convert innovation into compliant, market‑ready medicines.
How Impurity Risks Are Changing Quality Expectations
Impurities are not static risks. Changes in raw materials, suppliers, manufacturing processes, or storage conditions can significantly alter impurity profiles over time. As a result, pharmaceutical quality expectations are expanding beyond basic compliance to include proactive, lifecycle‑based control.
Today, impurity profiling is expected to support:
- Greater visibility into API and excipient composition and origin
- Detection and control of process‑related, degradation, and elemental impurities
- Risk assessment aligned with ICH guidelines and regional pharmacopoeias
- Demonstration of product consistency across suppliers and batches
For manufacturers, this means impurity risks must be assessed early in development, monitored throughout production, and managed continuously across global supply chains.
Emerging Regulatory Pressures for APIs and Excipients
Globally, pharmaceutical regulations continue to evolve in response to manufacturing complexity and patient safety concerns. Authorities are placing stronger emphasis on data integrity, impurity control, and supplier oversight, while increasing inspection frequency and enforcement actions.
Key regulatory trends shaping impurity profiling include:
- Stricter limits for elemental impurities under ICH Q3D
- Enhanced expectations for genotoxic and mutagenic impurity control
- Greater scrutiny of excipient quality and functionality
- Increased accountability across outsourced and multi‑tier supply chains
These pressures are driving manufacturers to adopt more comprehensive, data‑driven compliance strategies, supported by independent laboratory testing and verification.
Testing Enables Reliable Impurity Control and Stronger Supply Chains
Advanced analytical testing is central to effective impurity profiling. By identifying impurity risks early and monitoring them consistently, testing adds strength to supply chains by reducing variability, preventing recalls, and supporting predictable regulatory outcomes.
Through accredited laboratories and validated methodologies, Cotecna supports pharmaceutical manufacturers with reliable data that underpins both regulatory compliance and informed decision‑making.
Cotecna’s impurity profiling and testing services support:
- Identification and quantification of organic, inorganic, and elemental impurities
- Residual solvent and degradation product analysis
- Method development and validation aligned with regulatory expectations
- Stability testing to assess impurity evolution over product shelf life
By addressing impurity risks before they escalate, testing helps manufacturers reduce delays, avoid costly remediation, and protect product integrity.
Nitrosamine and Nitrite Testing Capabilities
In accordance with global regulatory guidelines, including ICH M7, US FDA and EMA, the control of nitrosamine impurities and nitrite levels has become a critical aspect of quality assurance in the pharmaceutical industry, particularly for Active Pharmaceutical Ingredients (APIs) and excipients. Nitrosamine and nitrite compounds are recognized as potential mutagenic impurities and therefore require strict monitoring to ensure patient safety and regulatory compliance.
To address these requirements, we offer comprehensive analytical testing services for nitrosamines and nitrites using highly sensitive and selective techniques, including:
- Liquid Chromatography coupled with Mass Spectrometry (LC-MS/MS) for trace-level quantification of nitrosamine impurities.
- Ion Chromatography (IC) for accurate determination of nitrite content in APIs and excipients.
These advanced analytical platforms enable detection at trace (ppb) levels, ensuring compliance with established acceptable intake limits and supporting risk assessment, method validation, and routine quality control testing.
Inspection and Supply Chain Oversight
Pharmaceutical supply chains often span multiple suppliers, subcontractors, and regions. In such environments, impurity risks frequently arise at handover points, where changes in raw materials, processes, or handling conditions can introduce variability.
Independent inspection strengthens supply chains by ensuring that APIs and excipients meet defined impurity specifications at every stage.
Cotecna inspection services support:
- Verification of supplier compliance and GMP alignment
- Oversight of raw material production and processing conditions
- Detection of deviations that may impact impurity profiles
- Improved transparency across complex pharmaceutical supply networks
Inspection adds resilience by helping manufacturers maintain control and consistency, even as sourcing strategies evolve.
Certification and Confidence in Pharmaceutical Markets
Certification and conformity assessment play an increasingly important role in demonstrating pharmaceutical quality, particularly when APIs or excipients are sourced globally or manufactured using innovative processes.
Certification provides a shared framework of trust, reducing uncertainty for regulators, commercial partners, and patients while strengthening supply chain credibility.
- Cotecna certification and verification services help pharmaceutical stakeholders:
- Demonstrate compliance with applicable GMP and regulatory standards
- Support audits, inspections, and market authorisations
- Reinforce confidence in supplier quality and impurity control
- Align quality commitments with patient safety expectations
Through structured, credible evidence, certification supports smoother market access and sustained regulatory confidence.
How Cotecna Supports Impurity Profiling and Pharmaceutical Quality
As a global TIC provider, Cotecna supports pharmaceutical manufacturers in managing impurity risks across APIs and excipients through integrated, lifecycle‑based solutions.
Cotecna’s approach is built on:
- Coordinated testing, inspection, and certification services
- Deep regulatory and pharmacopoeial expertise
- Risk‑based strategies focused on prevention, not correction
- Clear, actionable reporting to support quality decisions
This integrated model helps manufacturers translate complex analytical data into practical supply chain strength.
Enabling Safer Medicines and More Resilient Supply Chains
As pharmaceutical supply chains continue to globalise, impurity profiling will remain a cornerstone of patient safety, product quality, and regulatory compliance. Manufacturers that embed strong impurity management into their quality strategies will be better positioned to manage risk, maintain trust, and ensure continuity.
By partnering with Cotecna, pharmaceutical companies gain a trusted global partner that helps add strength to their supply chains through independent verification, technical excellence, and regulatory insight.
What This Means for Pharmaceutical Manufacturers
Impurity profiling is no longer a narrow analytical task; it is a strategic supply chain priority. To stay compliant and competitive, manufacturers should:
Integrate impurity profiling early in development
Impurity risks should be assessed during route selection, excipient qualification, and formulation development, not after scale‑up.
Prepare for increased regulatory scrutiny
Regulators expect clear impurity control strategies supported by robust data and documentation.
Rely on independent, data‑driven verification
Objective testing reduces assumptions and strengthens regulatory confidence.
Strengthen supplier and process oversight
New suppliers or changes in manufacturing increase impurity risk and require enhanced inspection.
Adopt an integrated TIC approach
Aligning testing, inspection, and certification reduces duplication, accelerates approvals, and strengthens supply chain resilience.
Ultimately, manufacturers that embed impurity profiling into their supply chain strategies improve predictability, reduce disruption, and protect patient trust.
Cotecna, Your Partner for Pharmaceutical Quality
By working with a global TIC partner like Cotecna, pharmaceutical manufacturers can manage impurity risks with confidence, ensuring APIs and excipients meet evolving safety, regulatory, and market expectations while strengthening supply chains end‑to‑end.
Cotecna CPS Global Network
Our network covers over 180 offices and laboratories globally.
Discover Cotecna Group Pharma Laboratories
- Neotron
- Shiva Analyticals
- Cotecna Life Sciences
To learn more about Cotecna Pharma Services, or to get a free quote, please contact us.
Follow us on Social Media to keep up with our Adding Strength to Supply Chains series.
About Shiva Analyticals
Shiva Analyticals is a leading testing laboratory in India, offering precise analytical services across industries such as pharmaceuticals, food, agriculture, and petroleum. Specializing in regulatory compliance and safety, Shiva uses state-of-the-art facilities and cGMP-compliant practices to deliver reliable, tailored solutions that help businesses ensure product quality and meet industry standards.